BullFrog AI Holdings Inc. announced in its annual letter to shareholders that the company made significant progress in 2025, emphasizing advances in technology development, commercial execution, and external validation. The company reported an evolution from platform development and early validation to commercialization and enterprise adoption during the year. BullFrog AI highlighted that its technology, based on causal and explainable artificial intelligence, is designed to augment human expertise in drug discovery and development. The company stated that the foundation built in 2025 positions it for a period of potentially meaningful commercial outcomes in 2026. No specific financial results or quantitative business results were disclosed in the announcement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BullFrog AI Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9618184-en) on December 30, 2025, and is solely responsible for the information contained therein.